Stock Worth Mentioning Today: What’s Ahead for ANI Pharmaceuticals Inc After Today’s Significant Increase?

Stock Worth Mentioning Today: What's Ahead for ANI Pharmaceuticals Inc After Today's Significant Increase?

The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) is a huge mover today! About 279,697 shares traded hands or 54.84% up from the average. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has risen 28.72% since April 4, 2016 and is uptrending. It has outperformed by 27.63% the S&P500.
The move comes after 8 months positive chart setup for the $582.38 million company. It was reported on Nov, 4 by Barchart.com. We have $62.85 PT which if reached, will make NASDAQ:ANIP worth $133.95 million more.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Ratings Coverage

Out of 5 analysts covering ANI Pharma (NASDAQ:ANIP), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. ANI Pharma has been the topic of 13 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The rating was downgraded by TheStreet on Wednesday, September 2 to “Buy”. Standpoint Research initiated ANI Pharmaceuticals Inc (NASDAQ:ANIP) rating on Friday, November 13. Standpoint Research has “Buy” rating and $54 price target. The company was downgraded on Tuesday, May 24 by Standpoint Research. The rating was upgraded by Roth Capital on Monday, September 28 to “Buy”. Raymond James initiated ANI Pharmaceuticals Inc (NASDAQ:ANIP) on Thursday, June 23 with “Strong Buy” rating. The firm has “Outperform” rating given on Friday, July 31 by Oppenheimer. Oppenheimer maintained ANI Pharmaceuticals Inc (NASDAQ:ANIP) rating on Friday, August 5. Oppenheimer has “Outperform” rating and $71 price target. TH Capital upgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) on Monday, September 28 to “Buy” rating. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) earned “Neutral” rating by TH Capital on Tuesday, August 4. The stock of ANI Pharmaceuticals Inc (NASDAQ:ANIP) has “Perform” rating given on Tuesday, July 19 by Oppenheimer.

According to Zacks Investment Research, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.”

Insitutional Activity: The institutional sentiment increased to 1.51 in 2016 Q2. Its up 0.46, from 1.05 in 2016Q1. The ratio increased, as 14 funds sold all ANI Pharmaceuticals Inc shares owned while 31 reduced positions. 28 funds bought stakes while 40 increased positions. They now own 5.41 million shares or 2.90% less from 5.57 million shares in 2016Q1.
Comerica Bank & Trust last reported 7,651 shares in the company. Citadel Ltd Liability holds 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 8,942 shares. Prudential reported 18,700 shares or 0% of all its holdings. Ardsley Advisory Prtn holds 0.44% or 45,000 shares in its portfolio. Tower Ltd Limited Liability Company (Trc) holds 0% or 224 shares in its portfolio. Morgan Stanley holds 3,139 shares or 0% of its portfolio. Moreover, Thomson Horstmann & Bryant Incorporated has 0.07% invested in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 9,862 shares. Federated Investors Pa owns 8,064 shares or 0% of their US portfolio. Pnc Financial Services Gp holds 0% of its portfolio in ANI Pharmaceuticals Inc (NASDAQ:ANIP) for 61,405 shares. The Illinois-based Ubs Asset Americas Incorporated has invested 0% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Tiaa Cref Investment Limited Com accumulated 0% or 25,631 shares. The Ontario – Canada-based Royal National Bank Of Canada has invested 0% in ANI Pharmaceuticals Inc (NASDAQ:ANIP). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 235 shares in its portfolio. Financial Architects Inc holds 0% or 275 shares in its portfolio. Goldman Sachs has 9,588 shares for 0% of their US portfolio.

Insider Transactions: Since August 8, 2016, the stock had 0 insider purchases, and 2 sales for $3.35 million net activity. 37,455 shares with value of $2.51M were sold by PRZYBYL ARTHUR on Monday, August 22. 12,500 shares were sold by Schrepfer Robert W, worth $838,209 on Monday, August 8.

More notable recent ANI Pharmaceuticals Inc (NASDAQ:ANIP) news were published by: Nasdaq.com which released: “ANI Pharmaceuticals, Inc. Bottom Line Rises 36% In Q3” on November 03, 2016, also Prnewswire.com with their article: “ANI Pharmaceuticals Announces FDA Approval and Immediate Launch of Nilutamide …” published on July 18, 2016, Prnewswire.com published: “ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and …” on October 27, 2016. More interesting news about ANI Pharmaceuticals Inc (NASDAQ:ANIP) were released by: Prnewswire.com and their article: “ANI Pharmaceuticals Announces Launch of Hydroxyprogesterone Caproate Injection …” published on June 28, 2016 as well as Prnewswire.com‘s news article titled: “ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full …” with publication date: August 04, 2016.

ANIP Company Profile

ANI Pharmaceuticals, Inc. (ANI), incorporated on April 11, 2001, is an integrated specialty pharmaceutical company. The Firm is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. The Firm has approximately two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. The Company’s two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet. The facilities are specialized with various capabilities, enabling the Company to manufacture liquid, powder, and oral solid-dose products, topicals, controlled substances and products. It also performs contract manufacturing for other pharmaceutical companies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment